← Back to Press PAGE

Nicolas Wolikow, on mission at Cure51

Cure51

Publication Date:

Aug 16, 2025

"Co-founder of this start-up, created at the end of 2022, Nicolas Wolikow wants to fight cancer. How? By identifying the biological mechanisms shared by the few thousand survivors who were initially thought to be doomed."

Read more

NEWS

THEY SPREAD THE WORD

Go to Press page

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

Defeating cancer: By identifying the biological mechanisms shared by tens of thousands of survivors of the most aggressive forms of cancer.

Aug 16, 2025

Join us to eradicate Cancer.

ROSALIND

Nicolas Wolikow, on mission at Cure51

Publication Date:

Aug 16, 2025

Table of Contents

THEY SPREAD THE WORD

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

Cancer Super-Survivors May Hold Keys to New Treatments

Researchers typically ask why people get cancer. What if they studied why some survive — or never develop the disease?

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

The Role of Real-World Evidence in Accelerating Drug Development

Nicolas Wolikow, Co-Founder and CEO at Cure51, on Ethical Principles in TechBio.

Defeating cancer: By identifying the biological mechanisms shared by tens of thousands of survivors of the most aggressive forms of cancer.

Aug 16, 2025